Zynerba Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Zynerba Pharmaceuticals

15/05/2023 13:01

* Zynerba Pharmaceuticals Inc  ZYNE.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Zynerba Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had fallen by
about 9.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Zynerba Pharmaceuticals Inc shares had fallen by 16.3%
this
quarter and lost 32.1% so far this year.
    * The company reported a quarterly loss of $10.11 million.
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.19          -0.21          Missed
 Dec. 31 2022      -0.18          -0.18          Met
 Sep. 30 2022      -0.22          -0.20          Beat
 Jun. 30 2022      -0.23          -0.24          Missed